STAT+: Trump most-favored nation drug pricing deals end after three years for some companies
Stat News • 2/27/2026
Summary
"Most-favored nation" drug pricing deals established under President Trump have ended after three years for some drugmakers, according to SEC filings.
Advertisement
Lindy Score Breakdown (V4.2)
0h
Age
1
Sources
from cluster
1
Hours Since Seen
Final Score12/100
CategoryAntiLindy
StatusActive
Recency Multiplier99% (0.5^1/48)
Hero EligibleYes
Score BreakdownRisk 70
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: Breaking news - too recent to assess longevity
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Justice Department backs AbbVie in its bid to overturn a Colorado law guiding a drug discount program
Stat News • 1 day ago
STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA
Stat News • 2 days ago
STAT+: Xenon’s seizure drug study reads out soon. Here’s what to expect
Stat News • 1 day ago
Trump touts lower drug costs and anti-fraud measures in lengthy State of the Union
Stat News • 2 days ago
STAT+: HHS adviser hopes prior authorization reform happens in ‘double-digit months,’ not years
Stat News • 2 days ago
STAT+: GSK picks up pulmonary hypertension drug with 35Pharma acquisition
Stat News • 2 days ago
STAT+: FDA Commissioner Marty Makary defends rare disease drug rejections, Vinay Prasad
Stat News • 1 day ago
STAT+: Novo Nordisk strikes deal with U.S. startup to develop oral obesity, diabetes drugs
Stat News • 2 days ago
STAT+: Up and down the ladder: The latest comings and goings
Stat News • Today
STAT+: Pharmalittle: We’re reading about FDA and a ‘smear campaign,’ Cigna buying a large pharmacy, and more
Stat News • Today